However, the levels of platelet-derived EVs in the plasma of these patients (Figure 3B), the concentration (Figure 3C), and the percentage (Figure 3D) of platelet-derived TF-bearing EVs were significantly increased in those patients who did not survive SARS-CoV-2 infection, indicating that this population of circulating EVs may not only become more abundant during the disease development but also that it may play an important part in the severity and mortality in COVID-19 patients. This evidence concerns the gene TF and COVID-19.